You wouldn’t be wrong if you said cannabidiol (CBD) has taken the world by storm. You wouldn’t expect a chemical extracted from cannabis to gather much support, but it has. In the U.S., industrial hemp, a cannabis variety with less than 0.3% of THC, was legalized by the 2018 Farm Bill, kick-starting the CBD craze.
A year later, the CBD sector is worth millions, and there are thousands of CBD products in circulation. With talk of the cannabidiol market being saturated, hemp producers have started turning to minor cannabinoids. Hemp produces over 100 of them, and although most of what we know about cannabinoids concerns CBD and THC, interest in the minor cannabinoids is peaking.
Cannabigerol (CBG) is one of the cannabinoids that has piqued farmers’ interest. Finding reliable genetics is one of the main hindrances to growing CBG-rich hemp, though, but that will soon change. In partnership with Swiss Cannabinoid, High Grade Hemp has released a new CBG hemp strain, Matterhorn CBG, a new boutique European CBG-rich cultivar.
For years, Matthias Ghidossi, the founder of Swiss Cannabinoid, has been cultivating his own terpenes and cannabinoid-rich hemp, and after a survey of thousands of hemp varieties, he concluded that the best varieties were terpene and CBG rich.
“We chose to focus on CBG due to its powerful efficacy in early trials. Over the past few years, more and more research has been conducted to understand the value of CBG. The early results of clinical testing in Europe are creating a lot of excitement in the field of science and medicine,” he says.
Cannabinoids are known to have medicinal properties. CBD is, without a doubt, the hottest one right now, and it’s been said to have a plethora of medical applications. Users claim it’s effective against a variety of ailments ranging from anxiety and high blood pressure to chronic pain and insomnia. There’s even a CBD-based drug used to treat seizures caused by two rare and hard to treat pediatric epilepsies.
Bodhi Urban, the CEO of High Grade Hemp Seed says, “At High Grade, we have focused our breeding program and partnerships to ensure farmers can grow proven, strong and diverse genetics. That’s one of the reasons we decided to work with Swiss Cannabinoid as a true genetics partner. Paving the way in CBG has been a logical next step, both in advancing the agricultural industry and also improving the availability of CBG products to U.S. consumers.”
High Grade will be giving away high-quality CBG genetics to 10 licensed farmers in the U.S., and the winners will be randomly selected and announced at the end of March 2020.
It would be great to hear what thoughts leading CBD companies like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) have about how quickly consumers will take to CBG.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.